Inhibikase Therapeutics (IKT) Short term Debt (2022 - 2025)
Historic Short term Debt for Inhibikase Therapeutics (IKT) over the last 4 years, with Q2 2025 value amounting to $37944.0.
- Inhibikase Therapeutics' Short term Debt fell 7507.36% to $37944.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $37944.0, marking a year-over-year decrease of 7507.36%. This contributed to the annual value of $110517.0 for FY2024, which is 2636.86% down from last year.
- As of Q2 2025, Inhibikase Therapeutics' Short term Debt stood at $37944.0, which was down 7507.36% from $74772.0 recorded in Q1 2025.
- In the past 5 years, Inhibikase Therapeutics' Short term Debt registered a high of $152224.0 during Q2 2024, and its lowest value of $37944.0 during Q2 2025.
- Its 4-year average for Short term Debt is $129475.2, with a median of $146368.5 in 2022.
- Its Short term Debt has fluctuated over the past 5 years, first skyrocketed by 491.52% in 2023, then crashed by 7507.36% in 2025.
- Over the past 4 years, Inhibikase Therapeutics' Short term Debt (Quarter) stood at $145836.0 in 2022, then increased by 2.92% to $150095.0 in 2023, then dropped by 26.37% to $110517.0 in 2024, then tumbled by 65.67% to $37944.0 in 2025.
- Its Short term Debt stands at $37944.0 for Q2 2025, versus $74772.0 for Q1 2025 and $110517.0 for Q4 2024.